SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to a significant price drop, sparking intense debate among investors regarding potential insider selling after a lock-up period expired. The community is actively analyzing trading volume and support levels, with some viewing the dip as a buying opportunity, while others express concern about continued selling pressure. Amidst the volatility, there's speculation about a potential short squeeze and comparisons to similar situations with other trading platforms.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors react to news of a potential partnership with OpenAI, with the community buzzing over the implications for AMD's role in the AI landscape and potential gains relative to competitors. Some traders are noting the stock's strong upward momentum and anticipating a continued rally, while others caution about overbought conditions and the risk of a pullback. Analyst upgrades and price target increases are further fueling the bullish sentiment around AMD.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amidst discussions around its high valuation and a former CEO's sale of a significant stake. While some community members express bullish sentiment and highlight the potential of quantum computing, others point to a lack of revenue and question the current market capitalization. Bearish investors are actively shorting the stock, anticipating a correction in the quantum computing sector.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate whether the stock is overvalued and due for a pullback, or if it still has room to run based on the future potential of quantum computing. Bears cite concerns over financials and potential offerings, while bulls point to the company's advancements and growing interest in the sector. Discussions also involve comparing RGTI to other quantum computing stocks and broader market trends.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending as investors discuss its recent capital raise and what it means for the company's future, with debate focusing on potential acquisitions and expansion; some traders are pointing to technical indicators suggesting oversold conditions. The quantum computing sector as a whole sees bullish and bearish sentiment as some question valuations. Overall, community members are actively debating whether QUBT presents a buying opportunity or if dilution concerns outweigh the positives.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending amid fluctuating sentiments, with community members debating whether it's experiencing a classic panic sell-off or a bear trap. Some traders are suggesting taking profits, while others urge holding for a potential surge, emphasizing the company's long-term prospects in the quantum computing sector. The conversation includes discussion of a newly launched ETF that shorts QBTS.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as the community discusses its potential as a quantum computing play, particularly in comparison to sector peers. The focus is on its merger with Infleqtion and potential for growth, with some highlighting its existing partnerships and revenue streams. Community members are weighing the potential for both common stock and warrants.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending amid high volume and news of multi-year AI cloud contracts, with the community discussing its potential for further gains and comparing it to other data center stocks. Some investors believe IREN is undervalued and poised for significant growth, while others are wary of overbought conditions and potential pullbacks. Discussions also include potential connections to upcoming data center events and mentions from industry figures.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to community discussion around its potential for a short squeeze, driven by high short interest and unusual options activity. Optimism surrounds the company's AI-driven drug discovery platform and potential catalysts, while some express concerns about insider selling. Additionally, the stock's connection to NVDA and the broader AI in healthcare sector are fueling interest.

American Rebel Holdings, Inc. engages in the design and marketing of branded safes, and personal security and self-defense products. It also designs and manufactures branded apparel and accessories. The company was founded on December 15, 2014 and is headquartered in Brentwood, TN.

American Rebel Holdings Inc

American Rebel Holdings is trending due to an announced 1-for-20 reverse stock split with a unique "round lot protection" provision guaranteeing those holding at least 100 shares will maintain that amount post-split, sparking community debate and speculative trading strategies. Traders are actively discussing the potential for a short squeeze and the stock's volatile history, while also evaluating the implications of insider selling and a recent resolution of debt with Bank of America. The community is weighing the risks and potential rewards of this situation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know 

Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.

Shares of Ovid Therapeutics Inc. (OVID) jumped 18% in the pre-market session on Friday after the company announced positive results from an early-stage trial of its OV329, as well as the pricing of a $175 million placement.OV329 is being developed for the potential treatment of rare and treatment-resistant forms of epilepsy and seizures. It is believed to work by reducing the activity of GABA-AT, an enzyme that degrades GABA, an important inhibitory neurotransmitter in the brain. An increase in levels of GABA in the brain can potentially suppress neuronal hyperexcitability, known to cause seizures, the company said.The early-stage <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-announces-positive-topline-results-for-the-next-generation-GABA-aminotransferase-inhibitor-OV329-that-demonstrate-strong-inhibitory-activity-and-a-potential-best-in-category-safety-profile/default.aspx">study</a>, which enrolled 68 healthy volunteers, was aimed at evaluating the safety, tolerability, pharmacokinetic, and pharmacodynamic activity of OV329. The drug demonstrated statistically significant inhibition of GABA-AT, matching or exceeding the inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor Vigabatrin (VGB), the company said. The drug also demonstrated a favorable safety and tolerability profile, it added. &nbsp;The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures. The study is expected to start in Q2 2026 and be completed in mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OVID">OVID stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_8_04_20_AM_png_cfbcdadc7f.webp" alt="OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>Separately, Ovid on Friday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-Therapeutics-Announces-Pricing-of-Private-Placement-Totaling-up-to-175-Million-in-Gross-Proceeds/default.aspx">announced</a> the pricing of a private placement totaling up to $175 million in proceeds. The financing transaction included participation from new investors alongside existing ones, the company said.The company stated that it intends to utilize the net proceeds from the initial closing of the financing deal, in conjunction with its existing cash, cash equivalents, and marketable securities, to fund research and development, general corporate expenses, and working capital requirements. It added that it expects its cash to fund its operating plan into 2028.A Stocktwits user applauded the funding news as “huge.”<stembedurl>https://stocktwits.com/Skeetz99/message/630905995</stembedurl>OVID stock is up 76% this year and approximately 45% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/esperion-shares-rally-after-patent-litigation-settlement-for-cholestrol-drugs/chCujWhR3Qb">Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures.

Equity

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +62.50% and +4,225.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts

Latest Ratings for OVID
 DateFirmActionFromTo Aug 2021CitigroupMaintainsNeutral Apr 2021Cantor FitzgeraldDowngradesOverweightNeutral Dec 2020CitigroupDowngradesBuyNeutral
 View More Analyst...

H.C. Wainwright Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ovid Therapeutics (OVID Research Report), with a price...

Buy Rating Affirmed for Ovid Therapeutics Amid Promising Pipeline and Stable Financial Outlook

TD Cowen analyst Ritu Baral has maintained their bullish stance on OVID stock, giving a Buy rating today. Ritu Baral has given his Buy rating due t...

Buy Rating Affirmed for Ovid Therapeutics on Advisory Expansion and Promising Epilepsy Drug Prospects

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Ovid Therapeutics (OVID Research Report), retaining the price target of $3.00...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During on April 1, 2014 and is headquartered in New York, NY.

Ovid Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

OVID
Ovid Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OVID News

OVID Ovid Therapeutics Inc